Syngene reported revenue of ₹910.6 Cr for the quarter, a 2% YoY increase, while profit after tax (PAT) before exceptional items saw a 37% YoY decline to ₹67.1 Cr.

For the half-year, revenue grew 6% YoY to ₹1,785.1 Cr, with PAT before exceptional items dipping 4% YoY to ₹153.8 Cr.

Operating EBITDA margins for the quarter and half-year were 22% and 23% respectively.

The company secured its first global phase III clinical trial and expanded its footprint to new regions.

Syngene is enhancing its Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end Antibody Drug Conjugate (ADC) manufacturing, with its U.S.

Bayview facility nearing operationalization.

The strategy emphasizes integrated CRDMO services across modalities, operational excellence, and a comprehensive digital transformation roadmap, including AI adoption and process automation (Project VEGA), to boost efficiency and client engagement.

Syngene also achieved high sustainability ratings, including top-tier Green Certification from My Green Lab.